Skip to main content
. 2016 Sep 26;7(45):73160–73170. doi: 10.18632/oncotarget.12248

Figure 3. Cyr61 suppression reduces the chances of distal metastatic tumor formation after PX.

Figure 3

Rate of forming detectable metastatic tumors in either liver or lung 8 weeks after PX (removal of original PDAC) in mice that had received AAV-shCyr61-LUC-GFP, compared to the mice that had received AAV-LUC-GFP. *p < 0.05. N = 20.